GNLX
GNLX clinical trials: GENELUX Corp
Every trial on ClinicalTrials.gov where GENELUX Corp is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 10
- Trials linked
- 7
- As lead sponsor
- 3
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
GNLX on the catalyst calendar · GNLX registry changes
- Primary completion Dec 2026Sponsor estimatePhase 3NCT05281471Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in...Genelux Corporation · Platinum-resistant Ovarian CancerRecruitingGNLXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2027Sponsor estimatePhase 2NCT06463665Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to...Genelux Corporation · Advanced Non-squamous Non-small-cell Lung CancerRecruitingGNLXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2021ActualPhase 1/Phase 2NCT02759588Olvi-Vec Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian CancerGenelux Corporation · Ovarian CancerCompletedGNLXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2014ActualPhase 1/Phase 2NCT01443260A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal CarcinomatosisGenelux GmbH · Peritoneal CarcinomatosisCompletedGNLXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2015ActualPhase 1NCT00794131Safety Study of GL-ONC1, an Oncolytic Virus, in Patients With Advanced Solid TumorsGenelux GmbH · Advanced Cancers (Solid Tumors)CompletedGNLXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT03420430Expanded Access to Provide GL-ONC1 for the Treatment of Advanced Cancers With No Standard of CareGenelux Corporation · Advanced Stage Cancer (Solid Tumor Disease for 4 Patients)No longer availableGNLXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2015ActualPhase 1NCT01584284Safety Study of Attenuated Vaccinia Virus (GL-ONC1)With Combination Therapy in Head & Neck CancerGenelux Corporation · Cancer of Head and NeckCompletedGNLXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1/Phase 2NCT07136285Olvi-Vec Combined With Platinum Plus Etoposide Therapy in Patients With Late Phase SCLCNewsoara HYK Biopharmaceutical (Shanghai) Co., Ltd. · SCLC, Extensive StageRecruitingGNLXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 24, 2024ActualPhase 1NCT01766739Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary...Memorial Sloan Kettering Cancer Center · Lung CancerCompletedGNLXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 6, 2019ActualPhase 1NCT02714374GL-ONC1 Administered Intravenously Prior to Surgery to Patients With Solid Organ CancersAndrew Lowy · Solid Organ CancersTerminatedGNLXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 10 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner